EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sustained Immune Persistence Five Years Post-Completion of Four-Dose sIPV Vaccination

Chu Kai, Li Yurong iD, Liu Sheng, Shan Yongmei, Wang Jianfeng, Li Xinge, Jiao Peng, Pan Hongxing

Vaccines · 27.02.2025 · 13 (3) · 253

DOI: 10.3390/vaccines13030253 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vaccines, online erschienen am 27.02.2025. Verfasst von Chu Kai und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Evaluation of Vaccines, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sinovac Biotech Co., Ltd. (Beijing, China).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The previous study assessed the immune durability of the Sabin strain inactivated poliovirus vaccine (sIPV) at four years of age; an update on its long-term persistence is warranted.

Methods

This Phase IV, open-label, parallel-controlled observational study, required by China’s National Medical Products Administration (NMPA), involves 6.5-year-old children who received four doses of sIPV or Salk IPV (wIPV) at 2, 3, 4, and 18 months during the Phase III trial. Participants are recruited in a 2:1 ratio and contribute blood samples for polio-neutralizing antibody (nAb) assays to determine non-inferiority of immune persistence.

Results

The study enrolled 483 participants aged 6.5 years in the 5-year Immune Persistence Set (IPS2), with 318 in the sIPV group and 165 in the wIPV group. Additionally, 387 participants (255 sIPV, 132 wIPV) with samples at six-time points were included in the Full Sequence Immune Persistence Set (IPS3). In IPS2, seropositivity rates (SPRs) for nAbs against serotypes 1–3 were over 99% in sIPV and 98% in wIPV. At 6.5 years, geometric mean titers (GMTs) were significantly higher in the sIPV group 543.96, 179.59 and 362.72 compared to the wIPV group 190.75, 81.05 and 203.95 for serotypes 1, 2 and 3, respectively. Participants in IPS3 demonstrated comparable SPRs and GMTs to IPS2, with values of 566.01 vs. 187.41 for serotype I, 177.55 vs. 78.01 for serotype II, and 365.47 vs. 190.31 for serotype III in the sIPV and wIPV groups, respectively. From one-month post-booster to 6.5 years, nAb GMTs showed declines: 19.35-fold for serotype I, 28.12-fold for serotype II, and 32.45-fold for serotype III in the sIPV group, and 23.42-fold, 23.83-fold, and 34.54-fold in the wIPV group, respectively. Non-inferiority of nAb SPRs and GMTs for sIPV compared to wIPV among participants aged 6.5 years was confirmed for all serotypes in IPS2 and IPS3.

Conclusions

The sIPV maintains good immunological persistence five years after four doses of vaccination, with nAb GMT exceeding the seroprotecting threshold, suggesting that booster doses might be currently unwarranted.

Schlagwörter

Stichwörter der Autor:innen

Sabin strainimmune persistenceinactivated poliovirus vaccine

Autor:innen und Institutionen

  • Institute of Clinical Evaluation of Vaccines, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China.
  • Sinovac Life Sciences Co., Ltd., Beijing 102629, China.
  • Pizhou City Center for Disease Control and Prevention, Pizhou 221000, China.
  • Guanyun County Center for Disease Control and Prevention Preventive, Lianyungang 222200, China.
  • Sinovac Biotech Co., Ltd., Beijing 100085, China.

ORCID-Profile: Li Yurong

Förderung

  • Sinovac Biotech Co., Ltd. (Beijing, China)

Zitieren

APA

Kai, C., Yurong, L., Sheng, L., Yongmei, S., Jianfeng, W., Xinge, L., Peng, J., & Hongxing, P. (2025). Sustained Immune Persistence Five Years Post-Completion of Four-Dose sIPV Vaccination. Vaccines, 13(3), 253. https://doi.org/10.3390/vaccines13030253

Vancouver

Kai C, Yurong L, Sheng L, Yongmei S, Jianfeng W, Xinge L, et al. Sustained Immune Persistence Five Years Post-Completion of Four-Dose sIPV Vaccination. Vaccines. 2025;13(3):253. doi:10.3390/vaccines13030253

BibTeX
@article{Kai2025,
  author = {Kai, Chu and Yurong, Li and Sheng, Liu and Yongmei, Shan and Jianfeng, Wang and Xinge, Li and Peng, Jiao and Hongxing, Pan},
  title = {Sustained Immune Persistence Five Years Post-Completion of Four-Dose sIPV Vaccination},
  journal = {Vaccines},
  year = {2025},
  volume = {13},
  number = {3},
  pages = {253},
  doi = {10.3390/vaccines13030253}
}
Kostenlos starten →